Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Accumulated Depreciation & Amortization rose 4210.53% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 4210.53%. This contributed to the annual value of $7.2 million for FY2024, which is 4693.88% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization stood at $2.7 million, which was up 4210.53% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $8.0 million in Q3 2022 and a low of $1.1 million during Q1 2023
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $3.2 million (2021), whereas its average is $3.6 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Accumulated Depreciation & Amortization skyrocketed by 20035.06% in 2021 and then tumbled by 8500.37% in 2023.
  • Rocket Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $3.2 million in 2021, then rose by 21.88% to $3.9 million in 2022, then rose by 25.64% to $4.9 million in 2023, then skyrocketed by 46.94% to $7.2 million in 2024, then plummeted by 62.5% to $2.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $2.7 million for Q3 2025, versus $4.5 million for Q2 2025 and $2.0 million for Q1 2025.